The functional consequences of alternative promoter use in mammalian genomes

RV Davuluri, Y Suzuki, S Sugano, C Plass… - Trends in Genetics, 2008 - cell.com
We are beginning to appreciate the increasing complexity of mammalian gene structure. A
phenomenon that adds an important dimension to this complexity is the use of alternative …

Silibinin-a promising new treatment for cancer

C Wing Ying Cheung, N Gibbons… - Anti-Cancer Agents …, 2010 - ingentaconnect.com
Silymarin and its major constituent, Silibinin, are extracts from the medicinal plant Silybum
marianum (milk thistle) and have traditionally been used for the treatment of liver diseases …

Arylamine N‐acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery

E Sim, A Abuhammad, A Ryan - British Journal of …, 2014 - Wiley Online Library
Arylamine N‐acetyltransferases (NAT s) are polymorphic drug‐metabolizing enzymes,
acetylating arylamine carcinogens and drugs including hydralazine and sulphonamides …

Arylamine N-acetyltransferases: from structure to function

E Sim, K Walters, S Boukouvala - Drug metabolism reviews, 2008 - Taylor & Francis
Arylamine N-acetyltransferases (NATs) are cytosolic conjugating enzymes which transfer an
acetyl group from acetylCoenzyme A to a xenobiotic acceptor substrate. The enzyme has an …

Arylamine N-acetyltransferases: structural and functional implications of polymorphisms

E Sim, N Lack, CJ Wang, H Long, I Westwood… - Toxicology, 2008 - Elsevier
Arylamine N-acetyltransferases (NATs) catalyse the N-acetylation of arylamines,
arylhydroxylamines and arylhydrazines with the acetyl group being transferred from …

Temporal modulation of differential alternative splicing in HaCaT human keratinocyte cell line chronically exposed to arsenic for up to 28 wk

AP Ferragut Cardoso, M Banerjee… - Environmental …, 2022 - ehp.niehs.nih.gov
Background: Chronic arsenic exposure via drinking water is associated with an increased
risk of developing cancer and noncancer chronic diseases. Pre-mRNAs are often subject to …

Extrahepatic metabolism at the body's internal–external interfaces

U Gundert-Remy, U Bernauer, B Blömeke… - Drug metabolism …, 2014 - Taylor & Francis
In general, xenobiotic metabolizing enzymes (XMEs) are expressed in lower levels in the
extrahepatic tissues than in the liver, making the former less relevant for the clearance of …

Arylamine N-acetyltransferases–from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention

E Sim, G Fakis, N Laurieri, S Boukouvala - Advances in pharmacology, 2012 - Elsevier
Arylamine N-acetyltransferases (NATs) are defined as xenobiotic metabolizing enzymes,
adding an acetyl group from acetyl coenzyme A (CoA) to arylamines and arylhydrazines …

Arylamine n-acetyltransferase i

RF Minchin, PE Hanna, JM Dupret, CR Wagner… - The international journal …, 2007 - Elsevier
Arylamine N-acetyltransferase I (NAT1) is a phase II enzyme that acetylates a wide range of
arylamine and hydrazine substrates. The NAT1 gene is located on chromosome 8 and …

Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues

A Husain, X Zhang, MA Doll, DF Barker… - Drug metabolism and …, 2007 - ASPET
Human N-acetyltransferase 2 (NAT2) genetic polymorphism is associated with drug toxicity
and/or carcinogenesis in various tissues. Knowledge of NAT2 gene structure and …